Effects of growth hormone treatment on very-low density lipoprotein apolipoprotein B100 turnover in adult hypopituitarism.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

GH was subsequently used in all patients for a further 6 months.

A 6-hour [1-13C] leucine infusion was administered at baseline and at 6 months.

Who Took Part

According to the abstract, 8 women were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a double-blind and placebo-controlled study.

Neither the women nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Apolipoprotein B-100, Apolipoproteins B, Cholesterol, HDL, Cholesterol, LDL, Hormone Replacement Therapy, Human Growth Hormone and Hypopituitarism.

What This Means in Plain Language

The paper is a double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2000 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.